Hyperglycemia-Pipeline Review, H1 2017

Hyperglycemia-Pipeline Review, H1 2017


  • Products Id :- GMDHC9458IDB
  • |
  • Pages: 30
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Hyperglycemia-Pipeline Review, H1 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Hyperglycemia-Pipeline Review, H1 2017, provides an overview of the Hyperglycemia (Metabolic Disorders) pipeline landscape.

Hyperglycemia is a condition that occurs when blood glucose levels get too high. Several factors can contribute to hyperglycemia, including food and physical activity choices, illness, non-diabetes medications, or not taking enough glucose-lowering medication. Symptoms include frequent urination, blurred vision, fatigue headache, nausea and vomiting, dry mouth, coma and confusion. Treatment includes anti-hyperglycemic therapy and insulin therapy.

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Hyperglycemia-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hyperglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Hyperglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperglycemia (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Hyperglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hyperglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hyperglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hyperglycemia (Metabolic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hyperglycemia (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hyperglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hyperglycemia-Overview

Hyperglycemia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hyperglycemia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hyperglycemia-Companies Involved in Therapeutics Development

Mitsubishi Tanabe Pharma Corp

Hyperglycemia-Drug Profiles

Drugs to Inhibit ABHD6 for Metabolic Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FGH-10019-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KR-62980-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize PST Receptor for Dysglycemic States-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DPP-IV for Hyperglycemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PEPCK for Type 2 Diabetes and Hyperglycemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Prokineticin Receptor for Metabolic Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Antagonize Glucagon Receptor for Hyperglycemia and Type 2 Diabetes-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hyperglycemia-Dormant Projects

Hyperglycemia-Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Hyperglycemia, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Hyperglycemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hyperglycemia-Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Hyperglycemia-Dormant Projects, H1 2017

Hyperglycemia-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Mitsubishi Tanabe Pharma Corp

Hyperglycemia Therapeutic Products under Development, Key Players in Hyperglycemia Therapeutics, Hyperglycemia Pipeline Overview, Hyperglycemia Pipeline, Hyperglycemia Pipeline Assessment

select a license
Single User License
USD 2000 INR 142380
Site License
USD 4000 INR 284760
Corporate User License
USD 6000 INR 427140

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com